Physician profile
Amanda Evans
NPI 1396402806
$2,352.15
in general payments reported to CMS, 2019-2025
38 companies · $478 in 2025
The $478 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $845 · 2023: $559 · 2024: $470 · 2025: $478.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,507.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,506.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $408.65 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $332.84 | 2023-2025 | |
| Glaxosmithkline, LLC. | $176.74 | 2022-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $121.99 | 2022-2025 | |
| Lilly USA, LLC | $96.54 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| E.R. Squibb & Sons, L.L.C. | $87.63 | 2022-2024 | Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.77 | 2022-2024 | Synjardy, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $69.45 | 2022-2025 | Farxiga |
| Takeda Pharmaceuticals U.S.A., INC. | $66.06 | 2022-2025 | Trintellix |
| Daiichi Sankyo INC. | $65.56 | 2022-2023 | Injectafer |
| Dexcom, INC. | $58.59 | 2025 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $52.87 | 2024-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $51.07 | 2023-2024 | Rexulti |
| Amgen INC. | $49.24 | 2022-2024 | Otezla, Repatha |
| Hologic Sales and Service, LLC | $46.35 | 2025 | Aptima |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.